Clinical Trials

International phase 2 randomised controlled trial comparing venetoclax-low dose cytarabine with standard intensive chemotherapy (daunorubicin, cytarabine and gemtuzumab ozogamicin) in newly diagnosed AML. Adaptive design allowing staged expansion to younger patients. CRUK/19/013.

International phase 3 randomised controlled trial comparing intensive treatment strategies for newly diagnosed FLT3-mutated AML. ISRCTN34016918.

International phase 3 randomised trial of newly diagnosed patients ineligible for intensive chemotherapy with IDH1m AML using ivosidenib plus azacitidine ± venetoclax.

International phase 3 randomised trial of newly diagnosed patients ineligible for intensive chemotherapy with either NPM1m or KMT2Ar AML 1:1 to venetoclax plus-azacitidine ± revumenib (menin inhibitor).

Multi-phase study of ASTX030 (oral azacitidine + cedazuridine) in combination with venetoclax in newly diagnosed AML patients ineligible for intensive chemotherapy. NCT04256317.

Phase 3 randomised, double-blind, placebo-controlled studies assessing ziftomenib in combination with either Venetoclax+Azacitidine or intensive (7+3) therapy in patients with untreated NPM1 mutated or KMT2A-rearranged AML

Phase 3 randomised, double-blind, placebo-controlled study of bleximenib, venetoclax and azacitidine for untreated NPM1 mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy

Phase 3, Double-Blind, Randomised, Placebo-Controlled Trial Of Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

Phase 1/2 study of the menin inhibitor bleximenib in relapsed/refractory (R/R) NPM1 mutated or KMT2A rearranged AML

Phase 1/2 study of the menin inhibitor enzomenib in relapsed/refractory (R/R) AML, ALL, MDS, and MM with KMT2A, NPM1, or other qualifying alterations

Phase 1 study to investigate the safety and efficacy of APL-4098 alone, and in combination with azacitidine or azacitidine and venetoclax in AML and MDS/AML

Phase 1/2 study of a CD33xVδ2 T-Cell Engager for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Phase 1/2 study of AZD3632 monotherapy or in combination with anticancer agents in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with HOX overexpression

BioDrive seeks to identify the most effective way to prevent and detect fungal infection in patients with acute leukaemia (acute myeloid leukaemia, acute lymphoblastic leukaemia, high-risk myelodysplastic syndromes and transformed myeloproliferative neoplasms); assessing if monitoring the risk of fungal infection by regular blood tests is safe and reduces the need to use antifungal drugs.

PROPEL is a multicentre randomised controlled trial comparing best practice usual care (BPUC) with a personalised prehabilitation care package (PPCP) incorporating a 12-month internal pilot, parallel process evaluation and economic evaluation. NIHR134257. Chief Investigators: Prof Janet Dunn, Prof Simon Stanworth.

MO-TRANS is a randomised multi-centre phase 3 trial of mocravimod maintenance treatment post allogeneic stem cell transplant

Phase 1/2 study assessing granulocyte augmentation to single-cord blood transplantation for high risk AML